|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We also observed enhanced miR-29a and reduced TTP levels in breast cancer patient samples, indicating relevance for human disease.
|
19247375 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
Additionally, a negative correlation between miR‑29a and REV3L mRNA expression levels in tumor tissues from patients with NSCLC was observed; low expression of miR‑29a and high expression of REV3L were closely associated with an advanced tumor‑node‑metastasis classification.
|
30535450 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The miR-29a expression was negatively correlated with the expression level of MTSS1 protein in NSCLC tissues (r=-0.762, p<0.05).
|
30229825 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
The results demonstrated that miR-29a was downregulated in NSCLC and the decreased expression level of miR-29a was significantly associated with advanced tumor-node-metastasis classification and metastasis.
|
28521487 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Evidence for the role of miR-29 in tumor malignancy and its prognostic value in overall survival (OS) and relapse-free survival (RFS) in non-small cell lung cancer (NSCLC) remains conflicting.
|
24909176 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
0.360 |
Biomarker
|
disease |
BEFREE |
Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens.
|
23043084 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.360 |
Biomarker
|
disease |
CTD_human |
Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation.
|
22048643 |
2012 |
|
Non-Small Cell Lung Carcinoma
|
0.360 |
AlteredExpression
|
disease |
BEFREE |
MiRNA expression profiling of human NSCLC cell lines indicated that miR-29a levels were reduced in more invasive cell lines.
|
19818597 |
2009 |
|
Malignant neoplasm of liver
|
0.320 |
Therapeutic
|
disease |
CTD_human |
Among them, miR-29a showed a positive therapeutic effect in liver cancer cells by inhibiting cell growth and inducing cell apoptosis, and PPM1D was confirmed to be the target gene of miR-29a.
|
21175813 |
2011 |
|
Malignant neoplasm of liver
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.
|
21625215 |
2011 |
|
Malignant neoplasm of liver
|
0.320 |
Biomarker
|
disease |
BEFREE |
Among the altered miRNA, miR-29a seemed to take a role in the mechanism of arsenic trioxide in liver cancer therapy.
|
21175813 |
2011 |
|
Liver neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
miR-29a promotes hepatitis B virus replication and expression by targeting SMARCE1 in hepatoma carcinoma.
|
28740345 |
2017 |
|
Liver neoplasms
|
0.310 |
Therapeutic
|
group |
CTD_human |
microRNA expression alteration after arsenic trioxide treatment in HepG-2 cells.
|
21175813 |
2011 |
|
Pancreatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.
|
27840954 |
2016 |
|
Neoplastic Cell Transformation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Aberrant expression of miR-638 contributes to benzo(a)pyrene-induced human cell transformation.
|
22048643 |
2012 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
|
20099276 |
2010 |
|
Mammary Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
|
20099276 |
2010 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
|
20099276 |
2010 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
miR-29a-5p was screened in a CAC mouse model by high-throughput microarray analysis and investigated in human colorectal cancer tissue samples and colon cell lines by quantitative reverse transcription polymerase chain reaction (Q-RTPCR).
|
31750910 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-29a is repressed by MYC in pancreatic cancer and its restoration drives tumor suppressive effects via downregulation of LOXL2.
|
31662451 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, mutant ACTB mRNA 3'-UTR promoted hepatocellular carcinoma cells migration and invasion in vitro and in vivo by up-regulating miR-1 target gene MET and miR-29a target gene MCL1.
|
31846694 |
2020 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutant ACTB mRNA 3'-UTR promotes hepatocellular carcinoma development by regulating miR-1 and miR-29a.
|
31846694 |
2020 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Meanwhile, klotho induced miR-29a expression in the PBMCs of HCs, while miR-29a expression was induced in the AD group by klotho and linagliptin.
|
31197641 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There was no difference found between those with TNM1 cancer and controls for both cancer types. miR-155, miR-34a and miR-29a were down-regulated in all patients with cancer compared to controls.
|
30348685 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Downregulation of miR-29a-3p and its tumor suppressive roles in cancer have been revealed by multiple reporters.
|
30588107 |
2019 |